Pages that link to "Q53251676"
Jump to navigation
Jump to search
The following pages link to Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. (Q53251676):
Displaying 50 items.
- Follicular lymphoma: 2012 update on diagnosis and management (Q22252956) (← links)
- Follicular lymphoma: 2011 update on diagnosis and management (Q26851450) (← links)
- Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma (Q27000310) (← links)
- Follicular lymphoma: 2014 update on diagnosis and management (Q27021850) (← links)
- Radioimmunotherapy of human tumours (Q28088825) (← links)
- A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma (Q33378233) (← links)
- Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides (Q33645793) (← links)
- Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer (Q33645821) (← links)
- Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas (Q33645841) (← links)
- Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data (Q33685903) (← links)
- Adaptive immunity in cancer immunology and therapeutics (Q33893934) (← links)
- Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (Q33915986) (← links)
- R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. (Q33934326) (← links)
- Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. (Q34253748) (← links)
- The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma (Q34418442) (← links)
- FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases (Q34585773) (← links)
- Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab (Q34631795) (← links)
- Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. (Q34646321) (← links)
- Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives (Q34700655) (← links)
- Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma (Q35052538) (← links)
- Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. (Q35056309) (← links)
- Cancer Radioimmunotherapy (Q35070045) (← links)
- Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901 (Q35100217) (← links)
- Prostate-specific membrane antigen-based therapeutics. (Q35132944) (← links)
- Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma (Q35186372) (← links)
- Thyroid dysfunction from antineoplastic agents (Q35500038) (← links)
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies (Q35501693) (← links)
- Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab (Q35780034) (← links)
- Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma (Q35786490) (← links)
- Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy (Q36010923) (← links)
- PET/CT Imaging and Radioimmunotherapy of Prostate Cancer (Q36085426) (← links)
- Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. (Q36221386) (← links)
- Therapy of newly diagnosed follicular lymphoma (Q36457298) (← links)
- Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model (Q36491547) (← links)
- Management of indolent lymphoma: where are we now and where are we going (Q36784860) (← links)
- Primary extraosseous Ewing sarcoma of the lung in children (Q36791086) (← links)
- Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma (Q36839758) (← links)
- Current treatment options in follicular lymphoma: science and bias (Q36966780) (← links)
- The curability of follicular lymphoma (Q36970950) (← links)
- The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas (Q36981694) (← links)
- Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer (Q37123705) (← links)
- Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival (Q37132248) (← links)
- Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study (Q37158257) (← links)
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. (Q37169112) (← links)
- Use of antibodies and immunoconjugates for the therapy of more accessible cancers (Q37174938) (← links)
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations (Q37201878) (← links)
- How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? (Q37208506) (← links)
- A rationale for the targeted treatment of oligometastases with radiotherapy (Q37212939) (← links)
- Treatment of follicular lymphoma: current status (Q37280915) (← links)
- Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma (Q37290469) (← links)